All of the treatment groups, Anti‐ELTD1 (**p = 0.0014), combined (****p < 0.0001), OKN (*p = 0.0126) and bevacizumab (*p = 0.0211), were successful in increasing the apoptotic activity within the tumours. This evidence concerns the gene ADGRL4 and neoplasm.